Form 4: Saba Capital Management Reports Transaction in abrdn Life Sciences Investors (HQL)
SEC Form 4 Filing
Saba Capital Management, a 10% owner of abrdn Life Sciences Investors (HQL), reported the purchase of 15,400 shares of common stock at $11.67 per share on April 14, 2025.
Summary
- Saba Capital Management, L.P., a 10% owner of abrdn Life Sciences Investors (HQL), filed a Form 4.
- The report indicates a transaction that occurred on April 14, 2025.
- Saba Capital Management acquired 15,400 shares of common stock at a price of $11.67 per share.
- Following the reported transaction, Saba Capital Management beneficially owns 3,078,916 shares indirectly.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing a transaction. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing reflects the trading activity of a significant shareholder in a publicly traded company. Such filings are common and provide transparency into the investment decisions of major stakeholders.
Stakeholder Impact
- The transaction may have a minor impact on the market price of HQL shares.
Key Dates
| Date | Description |
|---|---|
| 04/14/2025 | Date of transaction: Saba Capital Management acquired 15,400 shares of HQL. |
| 04/15/2025 | Date of signature for the Form 4 filing by Zachary Gindes and Boaz Weinstein. |
Keywords
Form 4, Saba Capital Management, abrdn Life Sciences Investors, HQL, Beneficial Ownership, Securities Transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.